23 filings
8-K
IMMU
Immunomedics Inc
26 Dec 19
Other Events
8:01am
8-K
IMMU
Immunomedics Inc
9 Dec 19
Immunomedics Announces Proposed Public Offering of Common Stock
4:35pm
8-K
IMMU
Immunomedics Inc
3 Dec 19
Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan
8:01am
8-K
IMMU
Immunomedics Inc
30 Oct 19
Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update
4:01pm
8-K
IMMU
Immunomedics Inc
30 Sep 19
Immunomedics Provides Corporate Update
8:00am
8-K
ca8rp58 v76m3wetitey
7 Aug 19
Immunomedics Reports Second Quarter 2019 Results and Provides Corporate Update
4:01pm
8-K
9hzys0x424v m2
7 Jun 19
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
wqzvy9c dk0jn8kvqe9
31 May 19
Departure of Directors or Certain Officers
4:30pm
8-K
trs9uhj trbe
9 May 19
Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update
7:06am
8-K
ln04g6v
29 Apr 19
Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan In East and Southeast Asia Excluding Japan
8:58am
8-K
inuwyva
29 Apr 19
Immunomedics Announces Departure of Chief Medical Officer
8:57am
8-K
u3woi 5u5lebn0qz
17 Apr 19
Amendments to Articles of Incorporation or Bylaws
4:47pm
8-K
bque7t2uw tz
15 Apr 19
Other Events
5:00pm
8-K
5sbo2kh5t
8 Apr 19
Entry into a Material Definitive Agreement
9:15am
8-K
mofqnloqs gcdm9f4uc
29 Mar 19
Entry into a Material Definitive Agreement
5:12pm
8-K
rg25cj4p ccxi5dczdrw
13 Mar 19
Departure of Directors or Certain Officers
4:41pm
8-K
uasx 0cxsq
11 Mar 19
Departure of Directors or Certain Officers
4:46pm
8-K
brhj1
8 Mar 19
Immunomedics Appoints Barbara G. Duncan to Board of Directors
6:04am
8-K
hneg5r
25 Feb 19
Board and Management Redesign to Accommodate Focused and Disciplined Strategy and Operating Model for 2019
4:15pm
8-K
d96nuhg
11 Feb 19
Immunomedics Announces Oral Presentation at the 2019 Genitourinary Cancers Symposium
5:25pm